Medesis Pharma SA (PA:ALMDP) — Market Cap & Net Worth
Market Cap & Net Worth: Medesis Pharma SA (ALMDP)
Medesis Pharma SA (PA:ALMDP) has a market capitalization of $1.80 Million (€1.54 Million) as of May 10, 2026. Listed on the PA stock exchange, this France-based company holds position #29775 globally and #559 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medesis Pharma SA's stock price €0.35 by its total outstanding shares 5146610 (5.15 Million). Analyse ALMDP cash flow metrics to see how efficiently the company converts income to cash.
Medesis Pharma SA Market Cap History: 2021 to 2025
Medesis Pharma SA's market capitalization history from 2021 to 2025. Data shows change from $31.05 Million to $2.11 Million (-55.31% CAGR).
Medesis Pharma SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medesis Pharma SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.41x
Medesis Pharma SA's market cap is 17.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $31.05 Million | $95.73K | -$2.65 Million | 324.33x | N/A |
| 2022 | $11.89 Million | $47.30K | -$2.76 Million | 251.38x | N/A |
| 2023 | $5.22 Million | $300.03K | -$3.96 Million | 17.41x | N/A |
Competitor Companies of ALMDP by Market Capitalization
Companies near Medesis Pharma SA in the global market cap rankings as of May 10, 2026.
Key companies related to Medesis Pharma SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.05 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #360 globally with a market cap of $74.28 Billion USD.
- UCB SA (BR:UCB): Ranked #510 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #569 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.05 Billion | $429.82 |
| #360 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.28 Billion | $714.89 |
| #510 | UCB SA | BR:UCB | $51.74 Billion | €234.10 |
| #569 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Medesis Pharma SA Historical Marketcap From 2021 to 2025
Between 2021 and today, Medesis Pharma SA's market cap moved from $31.05 Million to $ 2.11 Million, with a yearly change of -55.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €2.11 Million | +6.06% |
| 2024 | €1.99 Million | -61.98% |
| 2023 | €5.22 Million | -56.07% |
| 2022 | €11.89 Million | -61.71% |
| 2021 | €31.05 Million | -- |
End of Day Market Cap According to Different Sources
On May 10th, 2026 the market cap of Medesis Pharma SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.80 Million USD |
| MoneyControl | $1.80 Million USD |
| MarketWatch | $1.80 Million USD |
| marketcap.company | $1.80 Million USD |
| Reuters | $1.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medesis Pharma SA
Medesis Pharma S.A. operates as a biopharmaceutical company. The company's products include NanoLithium (NP03) for the treatment of Alzheimer's disease; NanosiRNA HD and NanoP42T to treat Huntington's disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nucl… Read more